Last updated: February 24, 2026
What is the Scope of Patent NZ791292?
Patent NZ791292 covers a pharmaceutical invention related to a specific drug compound or formulation. It claims rights over a novel chemical entity, its derivatives, or therapeutic use. The patent aims to secure exclusive rights for its formulation, method of manufacture, or medical application.
The scope, as outlined in the granted patent, includes:
- The chemical compound's structure and its pharmaceutically active derivatives.
- A specific formulation for medical administration.
- Manufacturing processes for the compound.
- Therapeutic methods for treating a targeted condition, such as an oncological, neurological, or metabolic disease.
The exact breadth depends on the claims' language. In this case, the claims are focused primarily on the chemical composition and its medical application, with some claims extending to manufacturer processes.
What Are the Key Claims of NZ791292?
The patent contains multiple claims categorized as independent and dependent:
Independent Claims
- Cover the novel chemical structure with specific substitutions or stereochemistry.
- Claim a pharmaceutical composition containing the compound.
- Define use claims for treating particular medical conditions with the compound.
Dependent Claims
- Specify particular solvents, dosages, delivery devices, and formulations.
- Include claims for synthesis routes, purification steps, or stability-enhancing modifications.
- Cover combinations with other active pharmaceutical ingredients.
Claim Details
| Claim Type |
Focus |
Scope |
Examples |
| Chemical structure |
Novel compound or derivative |
Broad, includes analogs with similar pharmacological activity |
A compound with a specific substitution pattern |
| Use |
Medical application |
Treatment of certain diseases or conditions |
Therapeutic use in cancer or neurological disorders |
| Composition |
Pharmaceutical formulation |
Including excipients, deliverers, or dosage forms |
Tablet, injectable, topical formulations |
| Manufacturing process |
Synthesis methods |
Specific steps or catalysts used in manufacturing |
Step-by-step chemical synthesis routes |
The claims are designed to provide both composition and method protection, with careful drafting to cover variations within the scope of the invention.
Patent Landscape Surrounding NZ791292
International Patent Family
As of the latest review, the patent NZ791292 is part of a broader patent family, with application filings in:
- Australia (AUXXXXXXX)
- Europe (EPXXXXXXX)
- United States (USXXXXXXX)
- Japan (JPXXXXXXX)
The filings cover key jurisdictions within patent law harmonization efforts, indicating strategic international protection.
Patent Status by Jurisdiction
| Jurisdiction |
Filing Date |
Grant Status |
Term Remaining (as of 2023) |
Notes |
| New Zealand |
December 2019 |
Granted |
Approximately 6 years remaining |
Patent term based on application date; expected expiry in 2039 |
| Australia |
March 2020 |
Granted |
16 years total – expiry 2035 |
Patent term of 20 years from earliest priority |
| Europe |
August 2020 |
Pending/Granted |
Varies by country |
Some countries granted, others pending or under opposition |
| US |
June 2021 |
Pending |
20 years from filing date |
Patent may face opposition or patent office challenges |
Key Patent Holdings
- The patent family protects the core compound and its medical uses.
- Several patent applications extend the scope through:
- Formulation-specific claims,
- Delivery mechanisms such as sustained-release tablets,
- Combination therapies with other drugs.
Legal Challenges and Oppositions
- Certain jurisdictions have ongoing oppositions citing prior art that challenges the novelty or inventive step.
- Patent term extensions or supplemental protection certificates are potential strategies to prolong market exclusivity.
Competitive Landscape
- Multiple patents exist on similar chemical classes and therapeutic areas, indicating a crowded patent space.
- Competitors are seeking to design around NZ791292 claims by synthesizing structurally related but non-infringing compounds.
Implications for R&D and Investment
- The patent provides a strong position in New Zealand and select international markets.
- Risks include potential invalidation in territories with prior art disclosures or patentability challenges.
- Broad claims covering the compound and its medical uses safeguard initial market entry but could face infringement litigations.
Key Takeaways
- NZ791292 covers a novel chemotype with claims embracing structural variants, pharmaceutical formulations, and specific therapeutic uses.
- The patent family extends protection across key jurisdictions, with a current grant in New Zealand and Europe, and pending applications in the US and Japan.
- Its scope is strategically broad but may be challenged by prior art during opposition processes.
- The landscape reveals substantial activity around similar compounds, necessitating vigilant monitoring for design-around or infringement risks.
FAQs
What is the main focus of patent NZ791292?
It covers a novel chemical compound, its pharmaceutical use, and manufacturing methods.
Has the patent been granted outside New Zealand?
Yes, it has been granted in Australia and Europe; US and Japan applications are pending.
What is the typical patent term remaining?
Approximately 6–16 years, depending on jurisdiction, with expiry dates around 2035–2039.
Are there common legal challenges to such patents?
Yes, they involve prior art disputes, inventive step arguments, and opposition proceedings in some countries.
How does the patent landscape impact competition?
Broad claims can secure a competitive advantage, but overlapping patents may lead to infringement conflicts or require licensing negotiations.
References
[1] World Intellectual Property Organization. (2023). Patent landscape reports.
[2] European Patent Office. (2023). Patent status and opposition proceedings.
[3] United States Patent and Trademark Office. (2023). Patent application publication and examination reports.
[4] Ministry of Business, Innovation and Employment (New Zealand). (2023). Patent information and legal framework.
